NewLink Genetics, which is developing a Phase 3 drug for surgically-resected pancreatic cancer patients, raised $43 million by offering 6.2 million shares (vs. planned 5.5 million) at $7, below the range of $10 to $12. At the offer price, NewLink commands a market value of $131 million. NewLink Genetics plans to list on the NASDAQ under the symbol NLNK. Stifel Nicolaus Weisel and Canaccord Genuity acted as lead managers on the deal.
